New Publication: Congenital myasthenic syndrome with mild intellectual disability caused by a recurrent SLC25A1 variant

We were pleased to collaborate with colleagues in the UK, India, Germany, and Spain on this brief communication reporting three additional families with congenital myasthenic syndrome (CMS) all harbouring the same homozygous missense variant in SLC25A1, confirming this as a CMS-associated gene. Interestingly the patients  with more severe mutations also demonstrated mitochondrial abnormalities, while the milder mutations affected primarily the neuromuscular junction. Unlike typical mitochondrial disease the muscle weakness was non-progressive. However, the mitochondrial changes could provide an explanation for the pre-synaptic nature of this CMS-causing variant.

The full open access publication can be found on the European Journal of Human Genetics website.

Congenital myasthenic syndrome with mild intellectual disability caused by a recurrent SLC25A1 variant
Sunitha Balaraju, Ana Töpf, Grace McMacken, Veeramani Preethish Kumar, Astrid Pechmann, Helen Roper, Seena Vengalil, Kiran Polavarapu, Saraswati Nashi, Niranjan Prakash Mahajan, Ines A. Barbosa, Charu Deshpande, Robert W. Taylor, Judith Cossins, David Beeson, Steven Laurie, Janbernd Kirschner, Rita Horvath, Robert McFarland, Nalini Atchayaram & Hanns Lochmüller
European Journal of Human Genetics (2019)

Abstract

Congenital myasthenic syndromes (CMS) are a clinically and genetically heterogeneous group of disorders caused by mutations which lead to impaired neuromuscular transmission. SLC25A1 encodes a mitochondrial citrate carrier, associated mainly with the severe neurometabolic disease combined D-2- and L-2-hydroxyglutaric aciduria (D/L-2-HGA).We previously reported a single family with a homozygous missense variant in SLC25A1 with a phenotype restricted to relatively mild CMS with intellectual disability, but to date no additional cases of this CMS subtype had been reported. Here, we performed whole exome sequencing (WES) in three additional and unrelated families presenting with CMS and mild intellectual disability to identify the underlying causative gene. The WES analysis revealed the presence of a homozygous c.740G>A; p.(Arg247Gln) missense SLC25A1 variant, the same SLC25A1 variant as identified in the original family with this phenotype. Electron microscopy of muscle from two cases revealed enlarged and accumulated mitochondria. Haplotype analysis performed in two unrelated families suggested that this variant is a result of recurrent mutation and not a founder effect. This suggests that p. (Arg247Gln) is associated with a relatively mild CMS phenotype with subtle mitochondrial abnormalities, while other variants in this gene cause more severe neurometabolic disease. In conclusion, the p.(Arg247Gln) SLC25A1 variant should be considered in patients presenting with a presynaptic CMS phenotype, particularly with accompanying intellectual disability.

Picture1

Read next...

New lab publication on riboflavin transporter deficiency model

New Publication: Development of a riboflavin-responsive model of riboflavin transporter deficiency in zebrafish

Riboflavin transporter deficiency (RTD) is a rare genetic disorder in children, characterised by progressive sensorimotor and cranial neuronopathy caused by mutations in riboflavin transporter protein-encoding...
Congratulations CNMD Ottawa on 25 years of neuromuscular research. Photo of all former and current directors of the Centre.

uOttawa Eric Poulin Centre for Neuromuscular Disease Celebrates 25 Years of Neuromuscular Research

New co-directors Dr Mireille Khacho and Dr Hanns Lochmüller begin their tenure On November 25th the University of Ottawa Eric Poulin Centre for Neuromuscular Disease...
Clinical trial update - Canadian Patient First in the World to Receive Trial Drug in Argenx DOK7-CMS Study

Canadian Patient Dosed in Argenx DOK7-CMS Study

Our clinical research team at the NeuroMuscular centre of The Ottawa Hospital is excited to share that a Canadian patient affected by DOK-7 Congenital Myasthenic...
New lab publication - Brain malformations and seizures by impaired chaperonin function of TRiC

New Publication: Brain malformations and seizures by impaired chaperonin function of TRiC

We are excited to share a new publication from our research team! The study “Brain malformations and seizures by impaired chaperonin function of TRiC” uncovers...
New leadership for the University of Ottawa Centre for Neuromuscular Disease, Drs Mireille Khacho and Hanns Lochmuller.

Drs Hanns Lochmüller and Mireille Khacho New Leaders of University of Ottawa Eric Poulin Centre for Neuromuscular Disease

We are delighted to share exciting news from the uOttawa Brain and Mind Research Institute (uOBMRI)! Drs. Hanns Lochmüller and Mireille Khacho have been appointed...
Dr Lola Lessard and Kelly Ho receive prestigious research poster awards

Lab Members Receive Research Poster Awards at National and International Conferences

Kelly Ho Receives Poster Award at World Muscle Society Congress Congratulations to PhD researcher Kelly Ho, whose poster presentation "Investigating muscle specific kinase antibody treatment...